Nice analogy ds around the house buying.Although, in my mind,...

Nice analogy ds around the house buying.

Although, in my mind, eBioscience and Affymatrix have already bought the house.

ebBio have the removal truck backing up the driveway ready to combine the old and new together, while Affy is checking the curtains to see if their gear will match as the salesman (ADO) has said it would.

The 4C tells us, what the CEO mentioned at the AGM around the 'second product opportunity' within this deal.

"Anteo is working closely with eBioscience, an Affymetrix company, to assist with and facilitate the rapid migration of a range of relevant tests to include the use of Mix&Go. The first products selected are bead-based immunoassays for use on flow cytometers.

In late September we shipped optimised multiplex products to the relevant site for pre-market testing prior to incorporation of Mix&Go into all products within that range of products. Mix&Go was shown to significantly improve the performance of the assays we developed.

Work has commenced on the second product opportunity under the Affymetrix Agreement. The initial data on microtitre plates is sufficiently promising for us to share it with our Affymetrix partners to assist in further scoping out the project."

The certainty of cashflow to remove the need for dilution is the key to the door........ looking forward to the house warming party!